Latest Interviews
"By developing intra-African energy infrastructure, we can reduce costs, improve energy access, and encourage local refining and petrochemical industries."
62228
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
62226
"Procos is poised for transformative growth in 2025. Our R11 facility will significantly enhance our small-scale production capacity, enabling us to meet the growing demand for high-quality, specialized APIs in the US market."
62224
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
62222
“Our strategy is straightforward: acquire underperforming assets, inject capital, bring in the right expertise, and turn these assets around, making them more investable.”
62217
“Cada año fortalecemos nuestra visión `multilatina´ para movernos con flexibilidad. Si una oportunidad no cristaliza en un país, podemos encontrarla en otro, así nos mantenemos atentos y ajustamos la estrategia a cada mercado.”